8-K: Xtant Medical Reports Q2 2026 Results, Revenue Declines

Xtant Medical Holdings, Inc. announced its second quarter 2026 financial results, reporting a significant decrease in revenue and a net loss, attributed to asset sales and changes in reimbursement.

Summary

• Xtant Medical Holdings, Inc. reported second quarter 2026 revenue of $23.0 million, a decrease from $35.4 million in the second quarter of 2025.
• The revenue decline is primarily due to the sale of non-core assets (Coflex/CoFix and international hardware business) and the cessation of license revenue.
• Gross margin decreased to 57.9% from 68.6% year-over-year, impacted by the loss of high-margin license revenue and increased inventory charges.
• Operating expenses increased to $22.5 million from $19.7 million, largely due to a $5.0 million exclusivity fee for a new distribution agreement.
• The company reported a net loss of $9.4 million for Q2 2026, compared to a net income of $3.6 million in Q2 2025.
• Non-GAAP adjusted EBITDA was a loss of $2.7 million, down from a positive $6.9 million in the prior year's quarter.
• Cash and cash equivalents stood at $9.9 million as of June 30, 2026, with $0.7 million in revolving credit facility availability.
• Full-year 2026 revenue guidance has been modestly reduced to a range of $99 million to $103 million.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative sentiment due to a significant revenue decline, increased operating expenses, and a shift from net income to a net loss, despite strategic initiatives.

Positives

• Launched Trivium Shaped, an extension of its premium demineralized bone matrix allograft line, designed for improved handling and placement.
• Announced an exclusive U.S. distribution agreement with Dilon Technologies for the HEMOBLAST Bellows product, adding a complementary hemostatic technology.
• Hired Dilon Technologies' approximately 20-person U.S. sales team to support Xtant's biologics portfolio.
• The company believes its current cash and credit facility availability are sufficient to fund operations for at least the next 12 months.

Negatives

• Total revenue for Q2 2026 decreased to $23.0 million from $35.4 million in Q2 2025.
• Gross margin declined to 57.9% from 68.6% year-over-year.
• Operating expenses increased to $22.5 million from $19.7 million, driven by a $5.0 million exclusivity fee.
• Reported a net loss of $9.4 million in Q2 2026, a significant shift from a net income of $3.6 million in Q2 2025.
• Non-GAAP adjusted EBITDA loss of $2.7 million in Q2 2026, compared to a positive $6.9 million in Q2 2025.
• Full-year revenue guidance has been reduced to $99 million $103 million from $101 million $105 million.

Risks

• The distribution agreement with Dilon Technologies may be terminated, potentially impacting the ability to recapture the $5.0 million exclusivity fee.
• Dilon Technologies may not be able to continue manufacturing and supplying the HEMOBLAST Bellows product.
• The success of the distribution arrangement and the HEMOBLAST Bellows product is subject to future U.S. sales and the impact of new sales personnel.
• Potential for future impairment charges to long-lived assets and goodwill, and write-downs of excess and obsolete inventory.
• Risks associated with acquisitions and dispositions, and the ability to implement future growth initiatives.
• Dependence on key independent agents for a significant portion of revenue.
• Effect of inflation, elevated interest rates, recessionary factors, and supply chain disruptions.
• Government and third-party coverage and reimbursement for its products.

Future Outlook

Xtant is modestly reducing its full-year 2026 guidance to a range of $99 million to $103 million, down from $101 million to $105 million, reflecting lower-than-expected Q2 biologics revenue and ongoing headwinds for its amnio product line.

Management Comments

• "The second quarter reflected continued execution of our strategy to broaden our core biologics portfolio while expanding access to more hospitals and surgeons."
• "The Dilon distribution agreement added a complementary hemostatic technology and significant commercial resources, which, together with the introduction of Trivium Shaped, strengthen our platform and position us for sustained long-term growth."

Industry Context

StockSavvy.ai notes that the medical technology sector, particularly in orthopedics and surgical solutions, is highly competitive and sensitive to reimbursement changes and product innovation. Xtant's strategic moves, like the Dilon distribution agreement and the launch of Trivium Shaped, aim to bolster its position in a market where companies often rely on specialized product lines and distribution networks for growth.

Stakeholder Impact

• Shareholders: Potential negative impact due to reduced revenue, increased losses, and lowered full-year guidance, which may affect stock price.
• Employees: The hiring of Dilon's sales team could positively impact employee growth and sales force capabilities.
• Suppliers: The company's financial performance and strategic shifts may influence relationships with suppliers.

Next Steps

• Host investor conference call and webcast to discuss Q2 2026 results.
• Continue execution of strategy to broaden core biologics portfolio.
• Expand access to more hospitals and surgeons.
• Leverage the Dilon distribution agreement and the HEMOBLAST Bellows product.
• Utilize the expanded sales team to support the biologics portfolio.
• Focus on sustained long-term growth.

Key Dates

Recommendation

The company is undergoing significant strategic shifts, including divestitures and new distribution agreements, which have led to a substantial decline in revenue and profitability in the current quarter. While new product launches and partnerships show promise, the reduced guidance and negative EBITDA indicate ongoing challenges. A 'hold' recommendation reflects the uncertainty and the need to observe the impact of these strategic changes on future performance before considering a more definitive investment stance.

Keywords

orthopedics, biologics, bone grafting, hemostasis, surgical solutions, medical technology, allograft, financial results